Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753970 · ClinicalTrials.gov registry record · Phase 1
Retina is a Marker for Cerebrovascular Heath
A Phase 1 study of Cerebral Small Vessel Diseases and Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04753970: Recruiting Phase 1 study of Cerebral Small Vessel Diseases and Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, sponsored by Mayo Clinic.
NCT04753970 is a Phase 1 study of Cerebral Small Vessel Diseases and Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04753970, a Phase 1 study of Cerebral Small Vessel Diseases and Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
Primary Outcome
change in total white matter disease volume
Conditions Studied
Interventions
- DRUG Cilostazol
Study Locations (1)
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-02-09 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT04753970 shows while recruiting
NCT04753970 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 4 conditions, with Cerebral Small Vessel Diseases appearing as the primary indexed condition, and to 1 intervention - of which Cilostazol is the first listed.
NCT04753970 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04753970 about?
NCT04753970 is a clinical study titled "Retina is a Marker for Cerebrovascular Heath". Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as bio...
What is the current status of trial NCT04753970?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2021-02-09. Estimated completion is 2026-06.
What conditions does trial NCT04753970 study?
This clinical trial studies the following conditions: Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease.
What interventions are being tested in trial NCT04753970?
The interventions under investigation include: Cilostazol (DRUG).
Who is sponsoring clinical trial NCT04753970?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04753970 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04753970's enrollment target sits among peer trials
100 547th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI